A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 19, 2023

Primary Completion Date

September 12, 2023

Study Completion Date

September 12, 2023

Conditions

Healthy Participants

Interventions

DRUG

Treatment A: Emraclidine 30mg IR tablets (reference)

IR oral tablets

DRUG

Treatment B: Emraclidine 30mg IR test tablets 1

IR oral tablets

DRUG

Treatment C: Emraclidine 30mg IR test tablets 2

IR oral tablets

DRUG

Treatment D: Emraclidine 30mg IR test tablets 3

IR oral tablets

Trial Locations (1)

Overland Park, Kansas, Overland Park